Skip to content
B
BiotechEdge
Start 14-Day Free Trial

Akero Therapeutics + Novo Nordisk

closed

$AKRO acquired by Novo Nordisk for $4.7B

Deal Summary

Deal Value
$4.7B
Price/Share
$54
Announced
Oct 9, 2025
Closed
Dec 9, 2025

Fund Positioning

9 of 20 tracked specialist biotech funds held $AKRO — based on SEC 13F filings.

FundSharesValueEntryAt Announcement
RTW Investments5.5M$260.1MMar 2025Yes
Avoro Capital Advisors4.0M$187.8MJun 2025Yes
Perceptive Advisors1.1M$53.9MMar 2025Yes
Redmile Group748K$35.5MMar 2025Yes
Rock Springs Capital627K$29.7MMar 2025Yes
OrbiMed Advisors526K$25.0MMar 2025Yes
EcoR1 Capital440K$23.5MMar 2025Yes
Eventide Asset Management435K$20.7MMar 2025Yes
Baker Bros. Advisors325K$15.4MMar 2025Yes
← All biotech acquisitions